Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568698 | 0.80 | GAA (0.49) | ABL1SRCSMN1; SMN2KDM4ELMNA | |
| SCHEMBL20569062 | 0.75 | SMN1; SMN2 (0.37) | ABL1SRCTRPA1SMN1; SMN2KDM4E | |
| SCHEMBL20077898 | 0.71 | CACNA1C (0.42) | SMN1; SMN2KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL30396884 | 0.69 | ABL1 (0.46) | ABL1SRCKDM4EALDH1A1HPGD | |
| SCHEMBL24190146 | 0.69 | ABL1 (0.46) | ABL1SRCKDM4EALDH1A1HPGD | |
| SCHEMBL2024463 | 0.69 | NR4A2 (0.47) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL536675 | 0.69 | NOTUM (0.51) | KDM4ELMNAALDH1A1HTTNOTUM | |
| SCHEMBL29575721 | 0.69 | NR4A2 (0.47) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL3343465 | 0.69 | NOTUM (0.50) | SMN1; SMN2ALDH1A1HPGDSCN9ANOTUM | |
| SCHEMBL536245 | 0.68 | TRPA1 (0.49) | TRPA1SMN1; SMN2KDM4EPDE7APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED | 2022-08-16 | — | — | US | disclosed |
| EP-3630728-B1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIV OXFORD INNOVATION LTD (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630728-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215799-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | MGAM, GAA, ALPI | ABL1 196/4885SRC 4166/4885TRPA1 4502/4885 |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | ABL1 196/4885SRC 4166/4885TRPA1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.